Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Elite Feature:   Find Similar Charts in Seconds

Learn How
Market News Market Pulse Stocks News ETF News Crypto News

SELLAS Life Sciences Group, Inc.

Contributing Author

Recent Articles by SELLAS Life Sciences Group, Inc.

Sep-25
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer SLS GlobeNewswire
Sep-02
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer SLS +7.11% GlobeNewswire
Aug-11
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update SLS SLS +6.52% GlobeNewswire
May-14
SELLAS Life Sciences to Participate in Upcoming Investor Conferences SLS +13.63% GlobeNewswire
May-12
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update SLS SLS +25.10% GlobeNewswire
Mar-19
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update SLS +5.05% SLS -8.46% GlobeNewswire
Mar-17
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference SLS -5.97% GlobeNewswire
Mar-12
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 SLS -8.21% GlobeNewswire
Jan-14
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe SLS GlobeNewswire
Dec-29
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) SLS +16.72% GlobeNewswire
Dec-07
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 SLS GlobeNewswire
Nov-12
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update SLS GlobeNewswire
Nov-03
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting SLS GlobeNewswire
Oct-27
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds SLS GlobeNewswire
Oct-22
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum SLS GlobeNewswire
Oct-13
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 SLS GlobeNewswire
Sep-30
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update SLS GlobeNewswire
Sep-11
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds SLS GlobeNewswire
Aug-12
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update SLS GlobeNewswire
Aug-07
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification SLS GlobeNewswire
Jul-15
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study SLS GlobeNewswire
Jul-07
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board SLS GlobeNewswire
Jun-24
SELLAS Life Sciences to be Added to Russell 3000 and Russell 2000 Indexes SLS GlobeNewswire
Jun-05
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts SLS GlobeNewswire
Jun-02
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting SLS -7.60% GlobeNewswire
May-20
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase SLS +10.86% GlobeNewswire
May-15
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML SLS +5.96% GlobeNewswire
May-13
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update SLS -8.44% SLS +7.09% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)